TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE
Approved 1975-10-29
25
Indications
--
Phase 3 Trials
50
Years on Market

DEXTROAMPHETAMINE SULFATE Approval History

Loading approval history...

What DEXTROAMPHETAMINE SULFATE Treats

2 indications

DEXTROAMPHETAMINE SULFATE is approved for 2 conditions since its original approval in 1975. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Narcolepsy
  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

DEXTROAMPHETAMINE SULFATE Boxed Warning

ABUSE, MISUSE, AND ADDICTION Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing dextroamphetamine sulfate, assess each patient’s risk for ...

Drugs Similar to DEXTROAMPHETAMINE SULFATE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 15
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 20
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 25
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 30
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADDERALL XR 5
AMPHETAMINE ASPARTATE
2 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
AMPHETAMINE SULFATE
AMPHETAMINE SULFATE
2 shared
PRINSTON INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DEXEDRINE SPANSULE
DEXTROAMPHETAMINE SULFATE
2 shared
IMPAX LABS INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 10
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 15
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 20
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
DYANAVEL XR 5
AMPHETAMINE
2 shared
TRIS PHARMA INC
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
EVEKEO
AMPHETAMINE SULFATE
2 shared
AZURITY
Shared indications:
NarcolepsyAttention Deficit Hyperactivity Disorder
METHYLIN
METHYLPHENIDATE HYDROCHLORIDE
2 shared
SPECGX LLC
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
RITALIN
METHYLPHENIDATE HYDROCHLORIDE
2 shared
Novartis
Shared indications:
Attention Deficit Hyperactivity DisorderNarcolepsy
ADZENYS XR-ODT
AMPHETAMINE
1 shared
NEOS THERAPS
Shared indications:
Attention Deficit Hyperactivity Disorder
APTENSIO XR
METHYLPHENIDATE HYDROCHLORIDE
1 shared
RHODES PHARMS
Shared indications:
Attention Deficit Hyperactivity Disorder
ARYNTA
LISDEXAMFETAMINE DIMESYLATE
1 shared
AZURITY
Shared indications:
Attention Deficit Hyperactivity Disorder
AZSTARYS
DEXMETHYLPHENIDATE HYDROCHLORIDE
1 shared
COMMAVE THERAP
Shared indications:
Attention Deficit Hyperactivity Disorder
CONCERTA
METHYLPHENIDATE HYDROCHLORIDE
1 shared
Johnson & Johnson
Shared indications:
Attention Deficit Hyperactivity Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEXTROAMPHETAMINE SULFATE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finalit...

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE, AND ADDICTION Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (se...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.